|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5652338A
(en)
|
1988-03-16 |
1997-07-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Neutrophil chemotactic factor
|
|
JPH03505037A
(ja)
|
1988-05-02 |
1991-11-07 |
大日本製薬株式会社 |
ヒト好中球走化因子ポリペプチドの製造方法
|
|
KR100197110B1
(ko)
|
1988-08-29 |
1999-06-15 |
로버트 란만 |
활성 사람 호중구 화학주성 인자 폴리펩티드의 제조방법
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5427098A
(en)
|
1988-12-22 |
1995-06-27 |
Biofield Corp. |
Noninvasive method for determining treatment based upon lesion cell proliferation measurements
|
|
GB8909218D0
(en)
|
1989-04-22 |
1989-06-07 |
Medical Res Council |
Improvements in or relating to enhancers
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
IE913192A1
(en)
|
1990-09-12 |
1992-02-25 |
Scripps Research Inst |
Active site of interleukin-8: polypeptide analogs and¹antibodies
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
|
US5776457A
(en)
|
1991-03-29 |
1998-07-07 |
Genentech, Inc. |
Antibodies to human PF4A receptor and compositions thereof
|
|
US5840856A
(en)
|
1991-03-29 |
1998-11-24 |
Genentech, Inc. |
Antibodies to a human PF4 superfamily receptor
|
|
US5919896A
(en)
|
1991-03-29 |
1999-07-06 |
Genentech, Inc. |
PF4A receptor
|
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
|
CA2105998C
(en)
|
1991-03-29 |
2003-05-13 |
James Lee |
Human pf4a receptors and their use
|
|
US5571702A
(en)
|
1991-03-29 |
1996-11-05 |
Genentech, Inc. |
Amplification method for detection of human PF4A receptors
|
|
US6087475A
(en)
|
1991-12-19 |
2000-07-11 |
Genentech, Inc. |
PF4A receptor
|
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
|
US5508717A
(en)
|
1992-07-28 |
1996-04-16 |
Sony Corporation |
Computer pointing device with dynamic sensitivity
|
|
US6200558B1
(en)
|
1993-09-14 |
2001-03-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
|
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6448379B1
(en)
|
1993-09-14 |
2002-09-10 |
Chiron Corporation |
IL8 inhibitors
|
|
US5702946A
(en)
|
1994-03-03 |
1997-12-30 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
|
|
US5874080A
(en)
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
|
GB2303238B
(en)
|
1994-04-28 |
1998-02-18 |
Music Vending Inc |
Vending system
|
|
CA2194907A1
(en)
|
1994-07-13 |
1996-02-01 |
Kouji Matsushima |
Reshaped human antibody against human interleukin-8
|
|
US5707621A
(en)
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
AU4771696A
(en)
|
1995-01-23 |
1996-08-14 |
Regents Of The University Of California, The |
Methods for the treatment of acid aspiration-induced acute lung injury
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1997039772A1
(fr)
|
1996-04-19 |
1997-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
|
|
EP1854481B1
(en)
|
1996-04-23 |
2014-07-16 |
Chugai Seiyaku Kabushiki Kaisha |
Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
|
|
CA2254782A1
(en)
|
1996-06-26 |
1997-12-31 |
Kenji Yokoi |
Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
|
|
CA2268085A1
(en)
|
1996-10-22 |
1998-04-30 |
Go Wakabayashi |
Sepsis remedy comprising anti-il-8 antibody as active ingredient
|
|
EP1415998A3
(en)
|
1997-02-21 |
2005-11-23 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
|
|
CN1068524C
(zh)
|
1997-06-23 |
2001-07-18 |
叶庆炜 |
一种治疗顽症牛皮癣的药物
|
|
AU2559799A
(en)
|
1998-01-22 |
1999-08-09 |
Genentech Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6015557A
(en)
|
1999-02-24 |
2000-01-18 |
Tobinick; Edward L. |
Tumor necrosis factor antagonists for the treatment of neurological disorders
|
|
US6419934B1
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
|
US6423321B2
(en)
|
1999-02-24 |
2002-07-23 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of sensorineural hearing loss
|
|
IL129180A0
(en)
|
1999-03-25 |
2000-02-17 |
Technion Res & Dev Foundation |
Method and pharmaceutical composition for wound healing
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
EP1210424B1
(en)
|
1999-08-23 |
2007-02-07 |
Dana-Farber Cancer Institute, Inc. |
Novel b7-4 molecules and uses therefor
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
|
DE19952622A1
(de)
|
1999-11-02 |
2001-05-10 |
Bayer Ag |
Verfahren zur Herstellung von rekombinantem Interleukin-8 und Interleukin-8 Muteinen
|
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
|
US6420346B1
(en)
|
2000-02-07 |
2002-07-16 |
Rappaport Family Institute For Research In The Medical Sciences |
Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
|
|
AR030753A1
(es)
|
2000-09-25 |
2003-09-03 |
Smithkline Beecham Corp |
Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
|
|
US7427665B2
(en)
|
2000-12-08 |
2008-09-23 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
WO2002077172A2
(en)
|
2001-03-23 |
2002-10-03 |
Board Of Regents, The University Of Texas System |
Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
|
|
JP2005520854A
(ja)
|
2002-03-19 |
2005-07-14 |
アブジェニックス・インコーポレーテッド |
慢性閉塞性肺疾患（ｃｏｐｄ）を治療するための方法
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7282568B2
(en)
|
2002-12-16 |
2007-10-16 |
Medarex, Inc. |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20050142136A1
(en)
|
2003-10-23 |
2005-06-30 |
Lary Suva |
Anti-interleukin 8 therapy for tumor osteolysis
|
|
CA2588613C
(en)
|
2004-11-23 |
2010-09-14 |
Pip Co., Ltd. |
Built-in wall water service box
|
|
MX2007013058A
(es)
|
2005-04-20 |
2008-02-22 |
Amgen Fremont Inc |
Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
|
|
RU2494107C2
(ru)
*
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
US20110105724A1
(en)
|
2007-08-16 |
2011-05-05 |
Stephanie Jane Clegg |
Novel compounds
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
JP6211597B2
(ja)
|
2012-05-01 |
2017-10-11 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
新規抗体
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
JO3580B1
(ar)
|
2013-03-15 |
2020-07-05 |
Lilly Co Eli |
أجسام مضادة لكيموكين elr+ cxc شامل
|
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
|
WO2016044189A1
(en)
*
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
|
|
TN2019000101A1
(en)
|
2015-05-29 |
2020-07-15 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof.
|
|
KR20230038311A
(ko)
*
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
US11299543B2
(en)
|
2016-06-02 |
2022-04-12 |
Bristol-Myers Squibb Company |
Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
|
|
LT3463457T
(lt)
|
2016-06-02 |
2023-09-11 |
Bristol-Myers Squibb Company |
Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
|
|
WO2017210637A1
(en)
*
|
2016-06-03 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
|
|
WO2019140150A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|